https://hstalks.com/category/764/cancer/?biosci New and updated series & talks on Cancer from HSTalks' Biomedical & Life Sciences Collection. daily 1 2006-01-01T12:00+00:00 Henry Stewart Talks en © Copyright Henry Stewart Talks Ltd. The Biomedical & Life Sciences Collection © Copyright Henry Stewart Talks Ltd. https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci Bladder cancer: incidence and epidemiology - Bladder cancer risk factors - Lynch syndrome - Bladder cancer: pathology, staging and diagnosis - Initial therapy for NMIBC (non-muscle-invasive bladder cancer) Bladder cancer: types, risk factors, diagnosis, treatment and prevention: introduction to bladder cancer Prof. Guru P. Sonpavde Bladder cancer: incidence and epidemiology, Bladder cancer risk factors, Lynch syndrome, Bladder cancer: pathology, staging and diagnosis, Initial therapy for NMIBC (non-muscle-invasive bladder cancer) 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci Ongoing clinical trials for bladder cancer - Enfortumab-vedotin & pembrolizumab as first-line therapy - Disitamab vedotin & toripalimab (PD1 inhibitor) for the treatment of metastatic UC - Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions - Remission with cisplatin-based NAC - mRNA-4157 (V940): customizable individualized mRNA immunotherapy - Adjuvant chemotherapy - Neoadjuvant Chemo-IO combination therapy Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials Prof. Guru P. Sonpavde Ongoing clinical trials for bladder cancer, Enfortumab-vedotin & pembrolizumab as first-line therapy, Disitamab vedotin & toripalimab (PD1 inhibitor) for the treatment of metastatic UC, Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions, Remission with cisplatin-based NAC, mRNA-4157 (V940): customizable individualized mRNA immunotherapy, Adjuvant chemotherapy, Neoadjuvant Chemo-IO combination therapy 2026-09-30 2026-09-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/21178/surgical-treatment-of-lymphedema-current-approache/?biosci The train station analogy - Lymph node transplant - Lymphovenous bypass - Excisional procedure - Axillary reverse mapping (ARM) - Lymphatic microsurgical preventive healing approach (LYMPHA) - Immediate lymphatic reconstruction - Predisposition to lymphedema - Mascagni Sappey pathway - Axillary and cephalic pathways - Long vs. short bundle - Mapping the lymphatic system Surgical treatment of lymphedema: current approaches & future directions Dr. Dhruv Singhal The train station analogy, Lymph node transplant, Lymphovenous bypass, Excisional procedure, Axillary reverse mapping (ARM), Lymphatic microsurgical preventive healing approach (LYMPHA), Immediate lymphatic reconstruction, Predisposition to lymphedema, Mascagni Sappey pathway, Axillary and cephalic pathways, Long vs. short bundle, Mapping the lymphatic system 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/24940/unlocking-a-new-class-of-cancer-targets-neoantigen/?biosci Public neoantigens - Alternative splicing-derived neojunctions - Cancer immunotherapy - Brain tumours (gliomas) - T-cell receptor (TCR)-based therapy - Cancer vaccines - Intratumour heterogeneity - Tumour-specific antigens - Human leukocyte antigen (HLA) presentation - Off-the-shelf immunotherapies Unlocking a new class of cancer targets: neoantigens from RNA splicing Dr. Hideho Okada Public neoantigens, Alternative splicing-derived neojunctions, Cancer immunotherapy, Brain tumours (gliomas), T-cell receptor (TCR)-based therapy, Cancer vaccines, Intratumour heterogeneity, Tumour-specific antigens, Human leukocyte antigen (HLA) presentation, Off-the-shelf immunotherapies 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci Cancer vaccines - Cancer immunotherapy - Ovarian cancer - Tumour antigens - Whole-cell vaccines - T-cell activation - Tumour microenvironment - Clinical development of immunotherapies Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy Prof. Raymond Goodrich Cancer vaccines, Cancer immunotherapy, Ovarian cancer, Tumour antigens, Whole-cell vaccines, T-cell activation, Tumour microenvironment, Clinical development of immunotherapies 2026-08-31 2026-08-31 The Biomedical & Life Sciences Collection https://hstalks.com/t/21838/current-emerging-therapies-for-the-management-of-p/?biosci Endometrial cancer - Classification of endometrial cancer - Single agent immunotherapy in biomarker selected endometrial cancers - First-line treatment of advanced or recurrent endometrial cancer - Adding PARP inhibition to first line - Adjuvant therapy - Antibody drug conjugates in endometrial cancer - Cell cycle checkpoint inhibitors in endometrial cancers - Hormonal therapy - Biomarker based therapy Current & emerging therapies for the management of patients with endometrial cancer Prof. Brian Slomovitz Endometrial cancer, Classification of endometrial cancer, Single agent immunotherapy in biomarker selected endometrial cancers, First-line treatment of advanced or recurrent endometrial cancer, Adding PARP inhibition to first line, Adjuvant therapy, Antibody drug conjugates in endometrial cancer, Cell cycle checkpoint inhibitors in endometrial cancers, Hormonal therapy, Biomarker based therapy 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/24748/dna-repair-mechanisms/?biosci DNA damage sources and types - DNA repair pathways (BER, NER, MMR) - DNA polymerase and ligase roles - Repair defects in cancer and aging - DNA repair in disease prevention and treatment DNA repair mechanisms DNA damage sources and types, DNA repair pathways (BER, NER, MMR), DNA polymerase and ligase roles, Repair defects in cancer and aging, DNA repair in disease prevention and treatment 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/23422/neoantigen-vaccines-in-cancer-immunotherapy-a-brea/?biosci Renal cell carcinoma - Personalized neoantigen vaccines - Cancer immunotherapy - Neoantigen targeting - T-cell immune responses - Immune checkpoint inhibitors - Adjuvant therapy - Clinical trials Neoantigen vaccines in cancer immunotherapy: a breakthrough in renal cell carcinoma Dr. David A. Braun Renal cell carcinoma, Personalized neoantigen vaccines, Cancer immunotherapy, Neoantigen targeting, T-cell immune responses, Immune checkpoint inhibitors, Adjuvant therapy, Clinical trials 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/22960/immunotherapy-in-cancer-research-recent-advancemen/?biosci Cancer immunotherapy - Immune checkpoint blockade - Personalized cancer vaccines - CAR-T & TCR cell therapy - Bispecific T-cell engagers - Biomarker discovery - AI & multi-omics in oncology - Glioblastoma and tumor microenvironment Immunotherapy in cancer research: recent advancements (2026) Prof. Mustafa Khasraw Cancer immunotherapy, Immune checkpoint blockade, Personalized cancer vaccines, CAR-T & TCR cell therapy, Bispecific T-cell engagers, Biomarker discovery, AI & multi-omics in oncology, Glioblastoma and tumor microenvironment 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection https://hstalks.com/t/24751/antibody-drug-conjugates-adcs/?biosci Antibody-drug conjugate concept - ADC structure and components - Targeted cancer cell delivery - Clinical ADC applications - ADC benefits over standard cancer therapy - Challenges in ADC development - Future directions in personalized medicine Antibody-drug conjugates (ADCs) Antibody-drug conjugate concept, ADC structure and components, Targeted cancer cell delivery, Clinical ADC applications, ADC benefits over standard cancer therapy, Challenges in ADC development, Future directions in personalized medicine 2026-07-30 2026-07-30 The Biomedical & Life Sciences Collection